What is Pine Pharmaceuticals?
Pine Pharmaceuticals operates as a 503B outsourcing facility, specializing in the compounding and repackaging of high-quality pharmaceutical products. Their offerings, including combination drops, intraocular injections, IV bags, and topical ophthalmics, are manufactured in an FDA-registered facility. The company actively partners with research organizations to develop custom compounded solutions for clinical trials and specialized projects, demonstrating a commitment to innovation and addressing unique patient care needs across ophthalmology, otolaryngology, and surgical practices.
How much funding has Pine Pharmaceuticals raised?
Pine Pharmaceuticals has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Pine Pharmaceuticals
PPP
Public-Private Partnership
What's next for Pine Pharmaceuticals?
The substantial late-stage funding indicates Pine Pharmaceuticals is poised for significant growth and operational scaling. This capital injection will likely be directed towards expanding manufacturing capacity, enhancing research and development initiatives for novel compounded solutions, and potentially broadening their market reach. The strategic investment signals confidence from backers in the company's business model and its capacity to meet the increasing demand for specialized pharmaceutical compounding services, further solidifying its role in supporting advanced patient care and clinical research.
See full Pine Pharmaceuticals company page
